Augmenting the effector phase of adoptive T cell immunotherapy of cancer

Adoptive T cell immunotherapy has shown significant promise in advanced melanoma, with over half of patients who failed standard treatments achieving objective clinical responses after receiving tumor‑specific T cells following nonmyeloablative lymphopenic conditioning. This work examines the T cell populations and molecular mechanisms that enhance anti‑tumor efficacy in this setting. We demonstrate that durable, potent anti‑tumor responses require the presence of both tumor‑specific CD4⁺ and CD8⁺ T cells in the lymphopenic host. Additionally, we show that T cells deficient in the ubiquitin‑specific protease Ubp43 exhibit superior therapeutic activity compared to wild‑type cells. These findings highlight key cellular components essential for effective adoptive T cell therapy and suggest a strategy to improve clinical outcomes by targeting Ubp43.